TY - JOUR
T1 - A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine
AU - Patel, Rikinkumar S.
AU - Mansuri, Zeeshan
AU - Motiwala, Fatima
AU - Saeed, Hina
AU - Jannareddy, Namrata
AU - Patel, Hiren
AU - Zafar, Muhammad Khalid
N1 - Publisher Copyright:
© The Author(s), 2019.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Recent reports state that the prevalence of tardive dyskinesia (TD) is 32% with typical antipsychotics, and 13% with atypical antipsychotics. Current evidence-based recommendations determine an unmet need for efficacious treatment of TD. This systematic review was planned to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine (DBZ), and valbenazine (VBZ). Of 75 PubMed search results, 11 studies met the review criteria. Efficacy and tolerability were demonstrated in a series of randomized, placebo-controlled clinical trials in our review study, and the Abnormal Involuntary Movement Scale response of ⩾50% reduction in score was robust for VBZ 80 mg/day in short-term and long-term studies. On the contrary, DBZ was equally efficacious at 12 mg twice daily, but additional information about long-term efficacy and persistence of effect is needed.
AB - Recent reports state that the prevalence of tardive dyskinesia (TD) is 32% with typical antipsychotics, and 13% with atypical antipsychotics. Current evidence-based recommendations determine an unmet need for efficacious treatment of TD. This systematic review was planned to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine (DBZ), and valbenazine (VBZ). Of 75 PubMed search results, 11 studies met the review criteria. Efficacy and tolerability were demonstrated in a series of randomized, placebo-controlled clinical trials in our review study, and the Abnormal Involuntary Movement Scale response of ⩾50% reduction in score was robust for VBZ 80 mg/day in short-term and long-term studies. On the contrary, DBZ was equally efficacious at 12 mg twice daily, but additional information about long-term efficacy and persistence of effect is needed.
UR - https://www.scopus.com/pages/publications/85081215193
UR - https://www.scopus.com/inward/citedby.url?scp=85081215193&partnerID=8YFLogxK
U2 - 10.1177/2045125319847882
DO - 10.1177/2045125319847882
M3 - Review article
AN - SCOPUS:85081215193
SN - 2045-1253
VL - 9
JO - Therapeutic Advances in Psychopharmacology
JF - Therapeutic Advances in Psychopharmacology
ER -